| Literature DB >> 33436582 |
Jong-Chan Park1,2,3,4, So-Yeong Jang5, Dongjoon Lee1,3, Jeongha Lee1, Uiryong Kang5, Hongjun Chang5, Haeng Jun Kim1,3, Sun-Ho Han1,2,3, Jinsoo Seo6, Murim Choi1, Dong Young Lee7,8,9, Min Soo Byun10, Dahyun Yi7, Kwang-Hyun Cho11, Inhee Mook-Jung12,13,14.
Abstract
Developing effective drugs for Alzheimer's disease (AD), the most common cause of dementia, has been difficult because of complicated pathogenesis. Here, we report an efficient, network-based drug-screening platform developed by integrating mathematical modeling and the pathological features of AD with human iPSC-derived cerebral organoids (iCOs), including CRISPR-Cas9-edited isogenic lines. We use 1300 organoids from 11 participants to build a high-content screening (HCS) system and test blood-brain barrier-permeable FDA-approved drugs. Our study provides a strategy for precision medicine through the convergence of mathematical modeling and a miniature pathological brain model using iCOs.Entities:
Year: 2021 PMID： 33436582 DOI： 10.1038/s41467-020-20440-5
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919